Modera Wealth Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,573 shares of the company’s stock after acquiring an additional 2,976 shares during the quarter. Modera Wealth Management LLC’s holdings in Eli Lilly and Company were worth $56,202,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Greenup Street Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 37.0% in the third quarter. Greenup Street Wealth Management LLC now owns 4,131 shares of the company’s stock worth $4,780,000 after acquiring an additional 1,115 shares during the period. CFC Planning Co LLC raised its holdings in shares of Eli Lilly and Company by 53.5% during the third quarter. CFC Planning Co LLC now owns 2,547 shares of the company’s stock valued at $2,949,000 after purchasing an additional 888 shares during the last quarter. Petros Family Wealth LLC lifted its position in Eli Lilly and Company by 4.2% during the third quarter. Petros Family Wealth LLC now owns 601 shares of the company’s stock valued at $695,000 after purchasing an additional 24 shares during the period. Whelan Financial lifted its position in Eli Lilly and Company by 22.9% during the third quarter. Whelan Financial now owns 740 shares of the company’s stock valued at $857,000 after purchasing an additional 138 shares during the period. Finally, Prosperitas Financial LLC boosted its holdings in Eli Lilly and Company by 9.2% in the third quarter. Prosperitas Financial LLC now owns 5,154 shares of the company’s stock worth $5,964,000 after purchasing an additional 436 shares during the last quarter. 82.53% of the stock is owned by institutional investors.
Key Eli Lilly and Company News
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
- Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
- Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
- Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
- Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report
Insider Activity
In other news, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 over the last 90 days. Corporate insiders own 0.14% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. Royal Bank Of Canada increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday. Argus raised their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a research note on Friday. Scotiabank lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,398.43.
View Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Trading Down 0.1%
Shares of LLY opened at $1,415.64 on Monday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $834.19 and a 1 year high of $1,449.68. The company has a 50 day simple moving average of $1,197.72 and a two-hundred day simple moving average of $1,092.57. The firm has a market cap of $1.33 trillion, a P/E ratio of 45.95, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the previous year, the firm earned $7.02 earnings per share. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
